Literature DB >> 19414792

Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome.

Dorothea Orth1, Abdul Basit Khan, Asma Naim, Katharina Grif, Jens Brockmeyer, Helge Karch, Michael Joannidis, Simon J Clark, Anthony J Day, Sonja Fidanzi, Heribert Stoiber, Manfred P Dierich, Lothar B Zimmerhackl, Reinhard Würzner.   

Abstract

Infections with enterohemorrhagic Escherichia coli (EHEC) are a major cause of hemolytic uremic syndrome (HUS). Shiga toxins (Stxs), especially Stx2, are believed to represent major virulence factors of EHEC, contributing to HUS pathogenesis. Beside EHEC-associated HUS, there are hereditary atypical forms of HUS, which are mostly caused by mutations of complement regulators. The aim of the present study was to investigate whether or not complement is also involved in the pathogenesis of EHEC-induced typical HUS, by being activated either directly or indirectly by involvement of its inhibitors. Purified Stx2 markedly activated complement via the alternative pathway and was found to bind to factor H (FH), however, only when it was active. No apparent cleavage or destruction of FH was visible, and cofactor activity in fluid phase was unaffected, but clearly delayed for surface-attached FH, where it is essential for host cell protection. Binding studies using FH constructs revealed that Stx2 binds to short consensus repeats (SCRs) 6-8 and SCRs18-20, but not to SCRs16-17, i.e., to regions involved in the surface recognition function of FH. In conclusion, complement, and in particular FH, not only plays an important role in atypical HUS, but most probably also in EHEC-induced HUS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19414792     DOI: 10.4049/jimmunol.0900151

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  62 in total

Review 1.  Shiga toxin-associated hemolytic uremic syndrome: advances in pathogenesis and therapeutics.

Authors:  Tania N Petruzziello-Pellegrini; Philip A Marsden
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-07       Impact factor: 2.894

2.  EspP, a serine protease of enterohemorrhagic Escherichia coli, impairs complement activation by cleaving complement factors C3/C3b and C5.

Authors:  Dorothea Orth; Silvia Ehrlenbach; Jens Brockmeyer; Abdul Basit Khan; Georg Huber; Helge Karch; Bettina Sarg; Herbert Lindner; Reinhard Würzner
Journal:  Infect Immun       Date:  2010-07-19       Impact factor: 3.441

Review 3.  Thrombotic microangiopathy with targeted cancer agents.

Authors:  John A Blake-Haskins; Robert J Lechleider; Robert J Kreitman
Journal:  Clin Cancer Res       Date:  2011-08-03       Impact factor: 12.531

Review 4.  Novel developments in thrombotic microangiopathies: is there a common link between hemolytic uremic syndrome and thrombotic thrombocytic purpura?

Authors:  Peter F Zipfel; Gunter Wolf; Ulrike John; Karim Kentouche; Christine Skerka
Journal:  Pediatr Nephrol       Date:  2011-06-14       Impact factor: 3.714

5.  Complement Gene Variants and Shiga Toxin-Producing Escherichia coli-Associated Hemolytic Uremic Syndrome: Retrospective Genetic and Clinical Study.

Authors:  Véronique Frémeaux-Bacchi; Anne-Laure Sellier-Leclerc; Paula Vieira-Martins; Sophie Limou; Theresa Kwon; Annie Lahoche; Robert Novo; Brigitte Llanas; François Nobili; Gwenaëlle Roussey; Mathilde Cailliez; Tim Ulinski; Georges Deschênes; Corinne Alberti; François-Xavier Weill; Patricia Mariani; Chantal Loirat
Journal:  Clin J Am Soc Nephrol       Date:  2019-01-23       Impact factor: 8.237

Review 6.  Shiga toxin pathogenesis: kidney complications and renal failure.

Authors:  Tom G Obrig; Diana Karpman
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

Review 7.  Shiga toxin triggers endothelial and podocyte injury: the role of complement activation.

Authors:  Carlamaria Zoja; Simona Buelli; Marina Morigi
Journal:  Pediatr Nephrol       Date:  2017-12-06       Impact factor: 3.714

Review 8.  Hemolytic uremic syndrome.

Authors:  Caterina Mele; Giuseppe Remuzzi; Marina Noris
Journal:  Semin Immunopathol       Date:  2014-02-14       Impact factor: 9.623

Review 9.  A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury.

Authors:  Sonata Jodele; Benjamin L Laskin; Christopher E Dandoy; Kasiani C Myers; Javier El-Bietar; Stella M Davies; Jens Goebel; Bradley P Dixon
Journal:  Blood Rev       Date:  2014-11-28       Impact factor: 8.250

Review 10.  Advances and challenges in the management of complement-mediated thrombotic microangiopathies.

Authors:  Jean-Claude Davin; Nicole C A J van de Kar
Journal:  Ther Adv Hematol       Date:  2015-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.